TY - BOOK PY - 2017 DA - 2017// TI - Remicade (infliximab) summary of product characteristics. London: EMA ID - ref1 ER - TY - STD TI - Janssen Biotech Inc. Remicade (infliximab) US prescribing information. Horsham, PA: Janssen Biotech, Inc.; 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761072s000lbl.pdf. Accessed 14 Aug 2017. UR - https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761072s000lbl.pdf ID - ref2 ER - TY - JOUR AU - Lipsky, P. E. AU - van der Heijde, D. M. AU - St Clair, E. W. AU - Furst, D. E. AU - Breedveld, F. C. AU - Kalden, J. R. PY - 2000 DA - 2000// TI - Infliximab and methotrexate in the treatment of rheumatoid arthritis: anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group JO - N Engl J Med VL - 343 UR - https://doi.org/10.1056/NEJM200011303432202 DO - 10.1056/NEJM200011303432202 ID - Lipsky2000 ER - TY - JOUR AU - St Clair, E. W. AU - van der Heijde, D. M. AU - Smolen, J. S. AU - Maini, R. N. AU - Bathon, J. M. AU - Emery, P. PY - 2004 DA - 2004// TI - Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial JO - Arthritis Rheum VL - 50 UR - https://doi.org/10.1002/art.20568 DO - 10.1002/art.20568 ID - St Clair2004 ER - TY - JOUR AU - Kalo, Z. AU - Voko, Z. AU - Ostor, A. AU - Clifton-Brown, E. AU - Vasilescu, R. AU - Battersby, A. PY - 2017 DA - 2017// TI - Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region JO - J Mark Access Health Policy VL - 5 UR - https://doi.org/10.1080/20016689.2017.1345580 DO - 10.1080/20016689.2017.1345580 ID - Kalo2017 ER - TY - JOUR AU - Cifaldi, M. AU - Renaud, J. AU - Ganguli, A. AU - Halpern, M. T. PY - 2016 DA - 2016// TI - Disparities in care by insurance status for individuals with rheumatoid arthritis: analysis of the medical expenditure panel survey, 2006-2009 JO - Curr Med Res Opin VL - 32 UR - https://doi.org/10.1080/03007995.2016.1227775 DO - 10.1080/03007995.2016.1227775 ID - Cifaldi2016 ER - TY - STD TI - Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency (EMA). Guideline on similar biological medicinal products. London: EMA; 2014. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf. Accessed 14 Aug 2017. UR - http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf ID - ref7 ER - TY - BOOK PY - 2015 DA - 2015// TI - Scientific considerations in demonstrating biosimilarity to a reference product. Guidance for industry. Silver Spring, MD: FDA ID - ref8 ER - TY - STD TI - IMS Institute for Healthcare Informatics. Delivering on the potential of biosimilar medicines: the role of functioning competitive markets. Parsippany, NJ: IMS Health and the IMS Institute for Healthcare Informatics; March 2016. https://www.medicinesforeurope.com/wp-content/uploads/2016/03/IMS-Institute-Biosimilar-Report-March-2016-FINAL.pdf. Accessed 21 Aug 2017. UR - https://www.medicinesforeurope.com/wp-content/uploads/2016/03/IMS-Institute-Biosimilar-Report-March-2016-FINAL.pdf ID - ref9 ER - TY - JOUR AU - Jha, A. AU - Upton, A. AU - Dunlop, W. C. AU - Akehurst, R. PY - 2015 DA - 2015// TI - The budget impact of biosimilar infliximab (Remsima®) for the treatment of autoimmune diseases in five European countries JO - Adv Ther VL - 32 UR - https://doi.org/10.1007/s12325-015-0233-1 DO - 10.1007/s12325-015-0233-1 ID - Jha2015 ER - TY - JOUR AU - Singh, S. C. AU - Bagnato, K. M. PY - 2015 DA - 2015// TI - The economic implications of biosimilars JO - Am J Manag Care VL - 21(16 Suppl) ID - Singh2015 ER - TY - JOUR AU - Jorgensen, K. K. AU - Olsen, I. C. AU - Goll, G. L. AU - Lorentzen, M. AU - Bolstad, N. AU - Haavardsholm, E. A. PY - 2017 DA - 2017// TI - Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial JO - Lancet VL - 389 UR - https://doi.org/10.1016/S0140-6736(17)30068-5 DO - 10.1016/S0140-6736(17)30068-5 ID - Jorgensen2017 ER - TY - STD TI - Pfizer Inc. Ixifi (infliximab-qbtx) US prescribing information. Pfizer Inc. 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761072s000lbl.pdf. Accessed 2 July 2018. UR - https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761072s000lbl.pdf ID - ref13 ER - TY - STD TI - European Medicines Agency. Zessly (infliximab) summary of product characteristics. 2018. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004647/WC500249647.pdf. Accessed 2 July 2018. UR - http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004647/WC500249647.pdf ID - ref14 ER - TY - JOUR AU - Derzi, M. AU - Johnson, T. R. AU - Shoieb, A. M. AU - Conlon, H. D. AU - Sharpe, P. AU - Saati, A. PY - 2016 DA - 2016// TI - Nonclinical evaluation of PF-06438179: a potential biosimilar to Remicade® (infliximab) JO - Adv Ther VL - 33 UR - https://doi.org/10.1007/s12325-016-0403-9 DO - 10.1007/s12325-016-0403-9 ID - Derzi2016 ER - TY - JOUR AU - Palaparthy, R. AU - Udata, C. AU - Hua, S. Y. AU - Yin, D. AU - Cai, C. H. AU - Salts, S. PY - 2018 DA - 2018// TI - A randomized study comparing the pharmacokinetics of the potential biosimilar PF-06438179/GP1111 with Remicade® (infliximab) in healthy subjects (REFLECTIONS B537-01) JO - Expert Rev Clin Immunol VL - 14 UR - https://doi.org/10.1080/1744666X.2018.1446829 DO - 10.1080/1744666X.2018.1446829 ID - Palaparthy2018 ER - TY - JOUR AU - Aletaha, D. AU - Neogi, T. AU - Silman, A. J. AU - Funovits, J. AU - Felson, D. T. AU - Bingham, C. O. PY - 2010 DA - 2010// TI - 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative JO - Ann Rheum Dis VL - 69 UR - https://doi.org/10.1136/ard.2010.138461 DO - 10.1136/ard.2010.138461 ID - Aletaha2010 ER - TY - JOUR AU - Hochberg, M. C. AU - Chang, R. W. AU - Dwosh, I. AU - Lindsey, S. AU - Pincus, T. AU - Wolfe, F. PY - 1992 DA - 1992// TI - The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis JO - Arthritis Rheum VL - 35 UR - https://doi.org/10.1002/art.1780350502 DO - 10.1002/art.1780350502 ID - Hochberg1992 ER - TY - STD TI - ClinicalTrials.gov. A study of PF-06438179 (infliximab-Pfizer) and infliximab in combination with methotrexate in subjects with active rheumatoid arthritis (REFLECTIONS B537–02). Registered on 21 Aug 2014. https://clinicaltrials.gov/ct2/show/NCT02222493. Accessed 14 Aug 2017. UR - https://clinicaltrials.gov/ct2/show/NCT02222493 ID - ref19 ER - TY - BOOK PY - 2013 DA - 2013// TI - Guidance for industry. Rheumatoid arthritis: developing drug products for treatment. Rockville, MD: U.S. Department of Health and Human Services, FDA, Center for Drug Evaluation and Research (CDER) ID - ref20 ER - TY - JOUR AU - Abe, T. AU - Takeuchi, T. AU - Miyasaka, N. AU - Hashimoto, H. AU - Kondo, H. AU - Ichikawa, Y. PY - 2006 DA - 2006// TI - A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis JO - J Rheumatol VL - 33 ID - Abe2006 ER - TY - JOUR AU - Maini, R. AU - St Clair, E. W. AU - Breedveld, F. AU - Furst, D. AU - Kalden, J. AU - Weisman, M. PY - 1999 DA - 1999// TI - Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT study group JO - Lancet VL - 354 UR - https://doi.org/10.1016/S0140-6736(99)05246-0 DO - 10.1016/S0140-6736(99)05246-0 ID - Maini1999 ER - TY - JOUR AU - Schiff, M. AU - Keiserman, M. AU - Codding, C. AU - Songcharoen, S. AU - Berman, A. AU - Nayiager, S. PY - 2008 DA - 2008// TI - Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate JO - Ann Rheum Dis VL - 67 UR - https://doi.org/10.1136/ard.2007.080002 DO - 10.1136/ard.2007.080002 ID - Schiff2008 ER - TY - JOUR AU - Westhovens, R. AU - Yocum, D. AU - Han, J. AU - Berman, A. AU - Strusberg, I. AU - Geusens, P. PY - 2006 DA - 2006// TI - The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial JO - Arthritis Rheum VL - 54 UR - https://doi.org/10.1002/art.21734 DO - 10.1002/art.21734 ID - Westhovens2006 ER - TY - JOUR AU - Zhang, F. -. C. AU - Hou, Y. AU - Huang, F. AU - Wu, D. -. H. AU - Bao, C. -. D. AU - Ni, L. -. Q. PY - 2006 DA - 2006// TI - Infliximab versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a preliminary study from China JO - APLAR J Rheumatol VL - 9 UR - https://doi.org/10.1111/j.1479-8077.2006.00186.x DO - 10.1111/j.1479-8077.2006.00186.x ID - Zhang2006 ER - TY - CHAP AU - Hua, S. Y. AU - Xu, S. AU - Barker, K. B. AU - Liao, S. M. AU - Li, S. ED - Barker, K. B. ED - Menon, S. M. ED - D’ Agostino, R. B. ED - Xu, S. ED - Jin, B. PY - 2017 DA - 2017// TI - Bayesian methods to assess bioequivalence and biosimilarity with case studies BT - Biosimilar clinical development: scientific considerations and new methodologies PB - CRC Press CY - Boca Raton, FL ID - Hua2017 ER - TY - JOUR AU - Alten, R. AU - van den Bosch, F. PY - 2014 DA - 2014// TI - Dose optimization of infliximab in patients with rheumatoid arthritis JO - Int J Rheum Dis VL - 17 UR - https://doi.org/10.1111/1756-185X.12202 DO - 10.1111/1756-185X.12202 ID - Alten2014 ER - TY - JOUR AU - Ariza-Ariza, R. AU - Navarro-Sarabia, F. AU - Hernandez-Cruz, B. AU - Rodriguez-Arboleya, L. AU - Navarro-Compan, V. AU - Toyos, J. PY - 2007 DA - 2007// TI - Dose escalation of the anti-TNF-α agents in patients with rheumatoid arthritis: a systematic review JO - Rheumatology (Oxford) VL - 46 UR - https://doi.org/10.1093/rheumatology/kel326 DO - 10.1093/rheumatology/kel326 ID - Ariza-Ariza2007 ER - TY - JOUR AU - Wu, E. AU - Chen, L. AU - Birnbaum, H. AU - Yang, E. AU - Cifaldi, M. PY - 2008 DA - 2008// TI - Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis JO - Curr Med Res Opin VL - 24 UR - https://doi.org/10.1185/03007990802229548 DO - 10.1185/03007990802229548 ID - Wu2008 ER - TY - JOUR AU - Lee, H. PY - 2014 DA - 2014// TI - Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars? JO - AAPS J VL - 16 UR - https://doi.org/10.1208/s12248-013-9534-y DO - 10.1208/s12248-013-9534-y ID - Lee2014 ER -